CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 257 enrolled
Drug / intervention
Karius Testother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04047719
NCT04047719N/ACompleted
CompareCT.gov

Pneumonia in the ImmunoCompromised - Use of the Karius Test for the Detection of Undiagnosed Pathogens

Karius, Inc.·observational·Posted Aug 7, 2019·Updated Feb 9, 2023

In Brief

An observational study evaluating Karius Test for Pneumonia, Bacterial and 4 related conditions. Completed, enrolled 257 participants across 10 sites.

Detailed Summary

Given the need for a more sensitive pathogen detection test in patients with immunocompromised pneumonia, this study will evaluate the performance of the Karius Test, a novel NGS blood test for the diagnosis of infectious diseases. We will compare the performance of the Karius Test to the results of microbiologic tests obtained as part of usual care for immunocompromised patients undergoing evaluation for suspected pneumonia.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPneumonia, Bacterial, Pneumonia, Viral, Pneumonia Fungal, Pneumonia Cavitary, Immunocompromised Host
CountriesUnited States
CollaboratorsDuke Clinical Research Institute

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedAug 7, 2019
Enrollment StartNov 5, 2019
Primary CompletionJun 6, 2022
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 6.9 years ago

Interventions

Karius Testother

Karius Test for detection of microbial cell free DNA (mcfDNA) in plasma